Celularity IncNASDAQ:CELUNASDAQ FSI:E. Delinquent (Issuer missed regulatory filing deadline)
- LAST PRICE3.1750
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.0800/ 88
- Ask / Lots3.2200/ 1
- Open / Previous Close--- / 3.1750
- Day Range---
- 52 Week Range
- Volume262
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Jul 31, 2024
Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023, from 8:30AM ET on Wednesday Jul 31, 2024 by Dow Jones
8:30AM ET on Wednesday Jul 31, 2024 by Dow JonesPress Release: Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023, from 8:30AM ET on Wednesday Jul 31, 2024 by Dow Jones
8:30AM ET on Wednesday Jul 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Celularity Inc | 69.8M | -0.3x | --- |
Prenetics Global Ltd | 70.9M | -1.3x | --- |
Aadi Bioscience Inc | 38.2M | -0.7x | --- |
Werewolf Therapeutics Inc | 97.0M | -1.7x | --- |
Gritstone bio Inc | 59.1M | -0.4x | --- |
Cara Therapeutics Inc | 18.7M | -0.2x | --- |
Company Information
Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It also develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance and Interfyl products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).
Contact Information
- Headquarters
- 170 Park AveFLORHAM PARK, NJ, United States 07932
- Phone
- 908-768-2170
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Executive Officer
- Robert Hariri
- Chief Financial Officer
- David Beers
- President - Degenerative Disease
- Stephen Brigido
- Senior Executive Vice President, Chief Administrative Officer, General Manager
- John Haines
- Director
- Shiu Fei Ling
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $69.8M |
|---|---|
Revenue (TTM) | $22.8M |
Shares Outstanding | 22.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-11.29 |
Book Value | $2.11 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 3.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -950.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
